Stephanie de Bono

6.6k total citations · 5 hit papers
49 papers, 3.0k citations indexed

About

Stephanie de Bono is a scholar working on Rheumatology, Hematology and Oncology. According to data from OpenAlex, Stephanie de Bono has authored 49 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Rheumatology, 14 papers in Hematology and 9 papers in Oncology. Recurrent topics in Stephanie de Bono's work include Rheumatoid Arthritis Research and Therapies (23 papers), Systemic Lupus Erythematosus Research (18 papers) and Autoimmune and Inflammatory Disorders Research (14 papers). Stephanie de Bono is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (23 papers), Systemic Lupus Erythematosus Research (18 papers) and Autoimmune and Inflammatory Disorders Research (14 papers). Stephanie de Bono collaborates with scholars based in United States, United Kingdom and Japan. Stephanie de Bono's co-authors include Terence Rooney, Douglas Schlichting, Scott D. Beattie, William L. Macias, Désirée van der Heijde, C. Gaich, Yoshiya Tanaka, Peter C. Taylor, Edward Keystone and Michael E. Weinblatt and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Stephanie de Bono

46 papers receiving 2.9k citations

Hit Papers

Baricitinib versus Placebo or Adalimumab in Rheumatoid Ar... 2016 2026 2019 2022 2017 2016 2018 2016 2016 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis
    2017 621 citations Peter C. Taylor, Edward Keystone et al. profile →
  2. Baricitinib in Patients with Refractory Rheumatoid Arthritis
    2016 458 citations Mark C. Genovese, Li Xie et al. profile →
  3. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial
    2018 356 citations Daniel J. Wallace, Richard Furie et al. The Lancet profile →
  4. Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease‐Modifying Antirheumatic Drug Treatment
    2016 309 citations Désirée van der Heijde, Stephanie de Bono et al. Arthritis & Rheumatology profile →
  5. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study
    2016 301 citations Maxime Dougados, Désirée van der Heijde et al. Annals of the Rheumatic Diseases profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Stephanie de Bono United States 19 2.0k 893 683 665 543 49 3.0k
Terence Rooney United States 28 2.9k 1.4× 1.4k 1.6× 932 1.4× 806 1.2× 857 1.6× 53 3.9k
Daniel Burge United States 14 2.6k 1.3× 1.5k 1.7× 266 0.4× 1.6k 2.4× 344 0.6× 23 3.9k
Patrick Verschueren Belgium 25 1.7k 0.8× 480 0.5× 230 0.3× 434 0.7× 259 0.5× 178 2.5k
Thierry Dervieux United States 29 1.1k 0.6× 659 0.7× 259 0.4× 499 0.8× 494 0.9× 82 2.9k
Scott W. Baumgartner United States 16 1.4k 0.7× 1.0k 1.1× 255 0.4× 766 1.2× 232 0.4× 18 2.5k
Ken J. Bulpitt United States 21 1.9k 1.0× 888 1.0× 217 0.3× 778 1.2× 326 0.6× 33 2.9k
Jacques Tébib France 25 1.3k 0.7× 386 0.4× 272 0.4× 669 1.0× 246 0.5× 91 2.3k
Josef S. Smolen Austria 24 2.9k 1.5× 966 1.1× 850 1.2× 1.2k 1.8× 421 0.8× 37 5.3k
Meinolf Suttorp Germany 32 524 0.3× 2.6k 2.9× 944 1.4× 951 1.4× 1.2k 2.2× 184 4.0k
Diane van der Woude Netherlands 32 2.8k 1.4× 463 0.5× 422 0.6× 1.1k 1.6× 343 0.6× 85 4.1k

Countries citing papers authored by Stephanie de Bono

Since Specialization
Citations

This map shows the geographic impact of Stephanie de Bono's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephanie de Bono with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephanie de Bono more than expected).

Fields of papers citing papers by Stephanie de Bono

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephanie de Bono. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephanie de Bono. The network helps show where Stephanie de Bono may publish in the future.

Co-authorship network of co-authors of Stephanie de Bono

This figure shows the co-authorship network connecting the top 25 collaborators of Stephanie de Bono. A scholar is included among the top collaborators of Stephanie de Bono based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stephanie de Bono. Stephanie de Bono is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Dörner, Thomas, Ronald van Vollenhoven, Andrea Doria, et al.. (2022). Baricitinib decreases anti-dsDNA in patients with systemic lupus erythematosus: results from a phase II double-blind, randomized, placebo-controlled trial. Arthritis Research & Therapy. 24(1). 112–112. 32 indexed citations
2.
3.
Dörner, Thomas, Yoshiya Tanaka, Michelle Petri, et al.. (2020). OP0045 DELINEATION OF A PROINFLAMMATORY CYTOKINE PROFILE TARGETED BY JAK1/2 INHIBITION USING BARICITINIB IN A PHASE 2 SLE TRIAL. Annals of the Rheumatic Diseases. 79. 29–30. 1 indexed citations
4.
Sims, Jonathan T., Venkatesh Krishnan, Sarah Engle, et al.. (2020). Characterization of the cytokine storm reflects hyperinflammatory endothelial dysfunction in COVID-19. Journal of Allergy and Clinical Immunology. 147(1). 107–111. 107 indexed citations
5.
Tanaka, Yoshiya, Bruno Fautrel, Edward Keystone, et al.. (2019). Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases. 78(7). 890–898. 23 indexed citations
6.
Silk, Maria, Daniel J. Wallace, Richard Furie, et al.. (2019). 199 Baricitinib in patients with systemic lupus erythematosus: results from a phase 2, randomized, double-blind, placebo-controlled study. Abstracts. A149.1–A149. 2 indexed citations
7.
Bingham, Clifton O., C. Gaich, Amy M. DeLozier, et al.. (2019). Use of daily electronic patient-reported outcome (PRO) diaries in randomized controlled trials for rheumatoid arthritis: rationale and implementation. Trials. 20(1). 182–182. 27 indexed citations
8.
9.
Tanaka, Yoshiya, Iain B. McInnes, Peter C. Taylor, et al.. (2018). Characterization and Changes of Lymphocyte Subsets in Baricitinib‐Treated Patients With Rheumatoid Arthritis. Arthritis & Rheumatology. 70(12). 1923–1932. 26 indexed citations
10.
Wallace, Daniel J., Richard Furie, Yoshiya Tanaka, et al.. (2018). Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. The Lancet. 392(10143). 222–231. 356 indexed citations breakdown →
11.
Genovese, Mark C., Désirée van der Heijde, Maxime Dougados, et al.. (2017). BARICITINIB INHIBITS RADIOGRAPHIC PROGRESSION OF STRUCTURAL JOINT DAMAGE AT 1 YEAR IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) AND AN INADEQUATE RESPONSE TO CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (CSDMARDS). Internal Medicine Journal. 47. 32–32. 1 indexed citations
12.
Bacci, Elizabeth D., Amy M. DeLozier, Chen‐Yen Lin, et al.. (2017). Psychometric properties of the single-item measure, severity of worst tiredness, in patients with moderately to severely active rheumatoid arthritis. Health and Quality of Life Outcomes. 15(1). 237–237. 2 indexed citations
13.
Dougados, Maxime, D. van der Heijde, Maria Greenwald, et al.. (2016). Baricitinib, an Oral Janus Kinase (JAK) 1/JAK2 Inhibitor, in Patients with Active Rheumatoid Arthritis (RA) and an Inadequate Response to cDMARD Therapy: Results of the Phase 3 RA-BUILD Study. The Journal of Rheumatology. 43(6). 1188–1188. 2 indexed citations
14.
Dougados, Maxime, Désirée van der Heijde, Ying‐Chou Chen, et al.. (2016). Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. Annals of the Rheumatic Diseases. 76(1). 88–95. 301 indexed citations breakdown →
15.
Taylor, Peter C., E C Keystone, D. van der Heijde, et al.. (2015). Baricitinib Versus Placebo or Adalimumab in Patients with Active Rheumatoid Arthritis (RA) and an Inadequate Response to Background Methotrexate Therapy: Results of a Phase 3 Study. Data Archiving and Networked Services (DANS). 67. 8–8. 15 indexed citations
16.
Dougados, Maxime, D. van der Heijde, Yu‐Chi Chen, et al.. (2015). LB0001 Baricitinib, an Oral Janus Kinase (JAK)1/JAK2 Inhibitor, in Patients with Active Rheumatoid Arthritis (RA) and An Inadequate Response to CDMARD Therapy: Results of the Phase 3 RA-Build Study. Annals of the Rheumatic Diseases. 74. 79–79. 24 indexed citations
17.
Bono, Stephanie de, Inez Schoenmakers, Mustapha Ceesay, et al.. (2010). Birth weight predicts bone size in young adulthood at cortical sites in men and trabecular sites in women from The Gambia. Bone. 46(5). 1316–1321. 17 indexed citations
18.
Prentice, Ann, Inez Schoenmakers, M. Ann Laskey, et al.. (2006). Symposium on ‘Nutrition and health in children and adolescents’ Session 1: Nutrition in growth and development Nutrition and bone growth and development. Proceedings of The Nutrition Society. 65(4). 348–360. 114 indexed citations
19.
Bono, Stephanie de & Bernard de Bono. (2001). With this ring………. Trends in Biochemical Sciences. 26(1). 14–14. 3 indexed citations
20.
Bono, Stephanie de, et al.. (1963). Evaluation des risques de traumatismes consécutifs à l'emploi du forceps ou de la ventouse de Malmström. Gynecologic and Obstetric Investigation. 155(6). 353–367. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Terence Rooney Breakdown of academic impact, for papers by Daniel Burge Breakdown of academic impact, for papers by Patrick Verschueren Breakdown of academic impact, for papers by Thierry Dervieux Breakdown of academic impact, for papers by Scott W. Baumgartner Breakdown of academic impact, for papers by Ken J. Bulpitt Breakdown of academic impact, for papers by Jacques Tébib Breakdown of academic impact, for papers by Josef S. Smolen Breakdown of academic impact, for papers by Meinolf Suttorp Breakdown of academic impact, for papers by Diane van der Woude
Rankless by CCL
2026